trametinib,dabrafenib
novartis
['trametinib', 'dabrafenib', 'melanoma']
phase ii of dabrafenib/trametinib +/- navetoclax in melanoma with orr 84%; cr 20% met co-primary endpoint of comparison to historical controls presented by zeynep eroglu #asco23 
Melanoma and high risk skin cancer medical oncologist. Studying hereditary and somatic genomics. CA explant in OH. (IO!) Sports fan, geek, and mommy. Tweets=me.